BTLA Antibodies and Uses Thereof

1 . A method for treatment of a human or animal body, comprising the administration of a BTLA antibody that blocks BTLA-HVEM interaction to said human or animal body.

2 . The method of claim 1 wherein said administration is for the treatment of a cancer or a chronic infection.

3 . A vaccine for the treatment of a cancer or a chronic infection comprising a BTLA antibody that blocks BTLA-HVEM interaction.

4 . A kit for the treatment of a cancer or a chronic infection comprising:

a) a BTLA antibody that blocks BTLA-HVEM interaction; and

b) a vaccine for the treatment of a cancer or a chronic infection.

5 . A method of claim 1 , wherein said BTLA antibody that blocks BTLA-HVEM interaction is a BTLA antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4123 or a derivative thereof.

6 . A BTLA antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4123.

7 . A BTLA antibody that blocks BTLA-HVEM interaction which comprises the CDRs of a BTLA antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4123.

8 . A hybridoma accessible under CNCM deposit number I-4123.

9 . A method of claim 2 wherein said BTLA antibody that blocks BTLA-HVEM interaction is a BTLA antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4123 or a derivative thereof.

10 . A vaccine of claim 3 wherein said BTLA antibody that blocks BTLA-HVEM interaction is a BTLA antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4123 or a derivative thereof.

11 . A kit of claim 4 wherein said BTLA antibody that blocks BTLA-HVEM interaction is a BTLA antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4123 or a derivative thereof.